Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 11:13 PM
Ignite Modification Date:
2025-12-26 @ 11:13 PM
NCT ID:
NCT05082012
Eligibility Criteria:
Inclusion Criteria:
Patients satisfying the following criteria will be considered the screening population and will be eligible for participation:
1. Male and females between the ages 14 and 58 years at the time of consent;
2. Closed physeal plates at the time of consent;
3. Intermetatarsal angle is between 10.0˚ - 22.0˚;
4. Hallux valgus angle is between 16.0˚ - 40.0˚;
5. Willing and able to adhere to early weight-bearing instructions post-operatively;
6. Capable of completing self-administered questionnaires;
7. Acceptable surgical candidate, including use of general anesthesia;
8. Female patients must be of non-child bearing potential or have a negative pregnancy test within 7 days prior to index procedure;
9. Willing and able to schedule index procedure within 3 months of consent and able to return for scheduled follow-up visits;
10. Willing and able to provide written informed consent.
Exclusion Criteria:
Patients satisfying the following criteria will not be eligible for participation:
1. Previous surgery for hallux valgus on operative side;
2. Previous surgeries on operative foot involving fusion of foot or ankle joints (other than hammertoe or lesser toes/digits);
3. Additional concomitant procedures outside of the 1st ray;
4. Moderate or Severe osteoarthritis of the MTP joint based on radiographic imaging (including lack of evident crista) or positive grind test;
5. Symptomatic flatfoot or asymptomatic flatfoot (defined as calcaneal inclination \<5˚and talonavicular subluxation/uncovering \>50%);
6. BMI \>40 kg/m²;
7. Current nicotine user, including current use of nicotine patch;
8. Current clinical diagnosis of diabetes with fasting plasma glucose \> 126 mg/dL and/or HbA1c ≥7.0;
9. Current clinical diagnosis of peripheral neuropathy or by assessment on 4-point monofilament test;
10. Current clinical diagnosis of fibromyalgia;
11. Current clinical diagnosis of Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy (CRPS/RSD);
12. Current uncontrolled hypothyroidism;
13. Previously sensitized to titanium;
14. Currently taking oral steroids or rheumatoid biologics;
15. Currently taking immunosuppressant drugs;
16. Insufficient quantity or quality of bone to permit stabilization, conditions that retard healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease;
17. Active, suspected or latent infection in the affected area;
18. Use of synthetic or allogenic bone graft substitutes;
19. Current diagnosis of metatarsus adductus (defined as MAA ≥ 23˚);
20. Known keloid and hypertrophic scar forming;
21. Scheduled to undergo a same-day bilateral procedure. Patient agrees to refrain from the Lapiplasty® Procedure (or other hallux valgus procedures) on contralateral foot for minimum of 6 months post index procedure;
22. Patient has previously been enrolled into this study for a contralateral procedure;
23. Scheduled for any concomitant procedure that would alter patient's ability to early weight-bear post-procedure;
24. Patient requires an incision \>4.0 cm to complete the procedure (determined pre-operatively or intra-operatively);
25. Patient is actively involved with a workman's compensation case or is currently involved in litigation;
26. Patient is currently or has participated in a clinical study in the last 30 days prior to signing informed consent or is considering participation in another research protocol during this study. Exceptions to this include survey clinical studies with no treatment or if subject is greater than 12 months post procedure in the Treace ALIGN3D™ study without ongoing protocol defined AE; these are not exclusionary;
27. Patient has a condition or finding that, in the opinion of the Investigator, may jeopardize the patient's well-being, the soundness of this clinical study, or could interfere with provision of informed consent, completion of tests, therapy, or follow-up.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
14 Years
Maximum Age:
58 Years
Study:
NCT05082012
Study Brief:
Protocol Section:
NCT05082012